Impairment of social behaviour in MAPT mutation carriers within the GENFI cohort

Neason M¹, Bocchetta M¹, Woollacott IOC¹, Shafei R¹, Moore KM¹, Convery RS¹, Cash D¹, Thomas D¹, Greaves CV¹, van Swieten J², Moreno F³, Sanchez-Valle R⁴, Borroni B⁵, Laforce R⁶, Masellis M⁷, Tartaglia C⁸, Graff C⁹, Galimberti D¹⁰, Rowe JB¹¹, Finger E¹², Synofzik M¹³, Vandenberghe R¹⁴, de Mendonça A¹⁵, Tagliavini F¹⁶, Santana I¹⁷, Ducharme S¹⁸, Butler C¹⁹, Gerhard A²⁰, Levin J²¹, Danek A²¹, Otto M²², Warren JD¹, Rohrer JD¹ on behalf of the Genetic FTD Initiative (GENFI)

¹Dementia Research Centre, UCL Queen Square Institute of Neurology, London, United Kingdom; ²⁻²² Principal Investigators of GENFI


INTRODUCTION

Early and progressive impairments in social behaviour underpin the core clinical features of FTD and may begin to manifest before clinical diagnosis¹. However, social symptoms are understudied compared to language and executive function domains. The Social Impairment Rating Scale (SIRS) quantitatively measures six social symptoms as part of a clinical interview [lack of adherence to social norms, social withdrawal, socioemotional detachment, lack of response to social cues, inappropriate trusting behaviour, and person recognition difficulties]² incorporated into the core Genetic FTD Initiative (GENFI) assessment.

AIMS

To explore the development of symptoms of social impairment and their neuroanatomical correlates in the GENFI cohort, including participants in both the presymptomatic and symptomatic stages of disease, with mutations in the GRN and MAPT genes and expansions in the C9orf72 gene.

Lack of adherence to social norms Noncarriers Presymptomatic C9orf72 Affected C9orf72 Presymptomatic GRN Affected GRN Presymptomatic MAPT Affected MAPT Social withdrawal Noncarriers Presymptomatic C9orf72 Affected C9orf72 Presymptomatic GRN Affected GRN Presymptomatic MAPT Affected MAPT



Lack of response to social cues

METHODS

Participants were recruited from the GENFI cohort: 204 mutation negative controls, 237 presymptomatic C9orf72, GRN and MAPT mutation carriers, and 90 symptomatic mutation carriers. Differences in the SIRS-sum of boxes (SIRS-SB) score and each individual SIRS subscore were analysed using a general linear model, controlling for age and gender. 282 of the mutation carriers had an available T1-weighted MRI scan of suitable quality for voxelbased morphometry (VBM) analysis. Using SPM12 we fit multiple regression models for each score in each mutation, including age, gender, scanner type and TIV as nuisance covariates. Statistical parametric maps were FWE-corrected (p<0.05) for multiple comparisons.

	Lack of adherence to social norms	Social withdrawal	Socioemotional detachment	Lack of response to social cues	 Inappropriate trusting behaviours 		SIRS-sum of boxes score	Table 1. <i>MAPT</i> mutation carriers experience severe
Controls vs Affected C9orf72	-0.715*	-1.482*	-1.172*	-1.082*	-0.594*	-0.403*	-5.448*	social impairment in all SIRS subdomains compared to controls (*p<0.001).
Controls vs Affected GRN	-0.445*	-1.429*	-0.978*	-0.816*	-0.336*	-0.217*	-4.223*	
Controls vs Affected MAPT	-1.370*	-1.385*	-1.348*	-1.350*	-0.961*	-0.878*	-7.291*	

12

10

RESULTS

Behavioural analyses. All symptomatic groups had a mean (SD) SIRS-SB score significantly greater than controls: MAPT 7.5 (4.5), C9orf72 5.7 (4.1) and GRN 4.5 (3.7), p < 0.001. Comparing individual subscores of the SIRS in presymptomatic and affected groups, MAPT carriers were the most severely affected in five out of six SIRS subdomains (Table 1).





Figure 1. Frequency of participants affected by SIRS subscores in the GENFI cohort.

CONCLUSION

Brain-behaviour analyses. Whilst all genetic groups experienced grey matter (GM) volume loss associated with increasingly severe symptoms of lack of adherence to social norms, social withdrawal, and lack of response to social cues, only MAPT experienced GM atrophy associated with all SIRS subdomains (Fig. 2). Distinct patterns of GM atrophy associated with increasing SIRS-SB score was seen in all genetic groups (Fig. 3).





MAP

MAPT mutation carriers exhibited more severe symptoms of social impairment (measured by SIRS), compared with the GRN and C9orf72 groups. The SIRS provides reliable measure of social а impairment in multiple domains, and may improve characterisation of FTD by providing a longitudinal outcome measure to track disease progression.

REFERENCES

1 Rohrer et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: A cross-sectional analysis. The Lancet Neurology, 2015. 2 Bickart et al. Atrophy in distinct corticolimbic networks in frontotemporal dementia relates to social impairments measured using the social impairment rating scale. Journal of Neurology, Neurosurgery and Psychiatry, 2014.







Person recognition difficulties

Figure 2. MAPT mutation carriers experience grey matter atrophy associated with all SIRS subdomains



Lack of response to social cues

Inappropriate trusting behaviours




Figure 3. Mutation-specific patterns of grey matter atrophy were associated with the SIRS-sum of boxes score in all three mutation carrier groups.

ACKNOWLEDGMENTS

We thank the research participants for their contribution to the study. The Dementia Research Centre is supported by Alzheimer's Research UK, Brain Research Trust, and The Wolfson Foundation. This work was supported by the NIHR Queen Square Dementia Biomedical Research Unit, the NIHR UCL/H Biomedical Research Centre and the Leonard Wolfson Experimental Neurology Centre (LWENC) Clinical Research Facility as well as an Alzheimer's Society grant. JDR is supported by an MRC Clinician Scientist Fellowship and has received funding from the NIHR Rare Disease Translational Research Collaboration. This work was also supported by the Medical Research Council UK GENFI grant and The Bluefield Project. IOCW is supported by an MRC Clinical Research Training Fellowship. KD is supported by an Alzheimer's Society PhD Studentship. RS is supported by an Alzheimer's Research UK Clinical Research Training Fellowship.